Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures, and have raised over $150M to date.

Profluent is seeking a rigorous and highly collaborative Associate Director - Director to lead in vivo pharmacology strategy and execution for our customized base editor therapeutics. You will oversee rodent and non-human primate (NHP) studies designed to evaluate editing activity, delivery, biodistribution, durability, tolerability, biomarker response, and translational potential. The successful candidate will serve as the in vivo pharmacology lead on cross-functional program teams, partnering closely with gene editing, protein engineering, delivery, computational biology, bioanalytics, translational science, and external CROs.

You will generate and interpret decision-quality in vivo datasets that guide editor selection, dose strategy, candidate nomination, and IND-enabling development plans. This is an excellent opportunity to help build the in vivo pharmacology function for a new class of AI-designed gene editing medicines and to shape how Profluent advances therapeutic candidates from discovery into development.

Responsibilities

Lead in vivo pharmacology strategy for Profluent’s customized base editor programs, spanning rodent and NHP studies from early proof-of-concept through candidate nomination and IND-enabling planning.

Qualifications

PhD or equivalent in pharmacology, physiology, molecular biology, genetics, bioengineering, or a related field, + 6-8 years of relevant industry experience in in vivo pharmacology and preclinical development Demonstrated experience designing, managing, and interpreting rodent and NHP pharmacology studies and supporting IND-enabling studies Experience with genetic medicines, such as genome editing, base editing, gene therapy, RNA medicines, oligonucleotide therapeutics, LNP delivery, viral vectors, or related modalities Strong understanding of PK/PD, dose response, biodistribution, target engagement, pharmacodynamic biomarkers, translational endpoints, and preclinical development strategy Experience leading CRO studies, including protocol design, vendor oversight, study monitoring, data Q

Associate Director - Director, In Vivo Pharmacology